The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials

This Viewpoint from US perspective argues that given limited vaccine supply for at least several months, only the participants receiving placebo who would be eligible for vaccination outside the trial should be offered access to the vaccines at this point.

Source:

Journal of the American Medical Association